ASTRO launches online practice quality improvement project

NewsGuard 100/100 Score

The American Society for Therapeutic Radiology and Oncology launched its Performance Assessment for the Advancement of Radiation Oncology Treatment (PAAROT) program on April 1 as a way for ASTRO members to satisfy the American Board of Radiology's Maintenance of Certification program requirements.

PAAROT was fully qualified as meeting the ABR's criteria for a Type-2 Practice Quality Improvement project in October 2007, and will allow participating physicians to analyze their strengths and areas that need improvement, as well as receive feedback on where specific changes can be made in their practices - all online. A practice inventory will then be compiled from which participants will select a minimum of one area to improve upon, which will be the focus of their PQI project.

Radiation oncologists are required to complete three PQI projects during a 10-year period to satisfy the Part IV requirements of the ABR-MOC program. At least one of the three PQI projects must be a Type-2 project, such as the PAAROT program. These courses are only required for radiation oncologists with time-limited certificates that were first issued by the ABR in 1995. However, all practicing radiation oncologists are encouraged to participate in MOC.

"PAAROT will be a very convenient way for ASTRO members to complete their Maintenance of Certification requirements and continue their education in the ever-evolving field of radiation oncology," said Laura I. Thevenot, ASTRO's Chief Executive Officer. "At ASTRO we are committed to providing our members with the tools they need to provide their radiation therapy patients with the best possible care."

PAAROT is available free to ASTRO members through December 31, 2008.

ASTRO is the largest radiation oncology society in the world, with more than 9,000 members who specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, biology and physics, the Society is dedicated to improving patient care through education, clinical practice, advancement of science and advocacy.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Immunotherapy breakthrough: Pembrolizumab extends time to recurrence in aggressive bladder cancer